Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Wages, Salaries and Other
Ratios

Revolution Medicines (RVMD) Leases (2020 - 2025)

Revolution Medicines has reported Leases over the past 6 years, most recently at $132.1 million for Q4 2025.

  • Quarterly results put Leases at $132.1 million for Q4 2025, up 12.38% from a year ago — trailing twelve months through Dec 2025 was $132.1 million (up 12.38% YoY), and the annual figure for FY2025 was $132.1 million, up 12.38%.
  • Leases for Q4 2025 was $132.1 million at Revolution Medicines, down from $134.4 million in the prior quarter.
  • Over the last five years, Leases for RVMD hit a ceiling of $134.4 million in Q3 2025 and a floor of $25.0 million in Q1 2023.
  • Median Leases over the past 5 years was $59.1 million (2021), compared with a mean of $70.7 million.
  • Biggest five-year swings in Leases: skyrocketed 215.25% in 2021 and later plummeted 57.32% in 2023.
  • Revolution Medicines' Leases stood at $59.7 million in 2021, then dropped by 7.73% to $55.1 million in 2022, then surged by 40.07% to $77.1 million in 2023, then skyrocketed by 52.35% to $117.5 million in 2024, then increased by 12.38% to $132.1 million in 2025.
  • The last three reported values for Leases were $132.1 million (Q4 2025), $134.4 million (Q3 2025), and $114.0 million (Q2 2025) per Business Quant data.